BAGSVAERD, Denmark I January 29, 2021 I Novo Nordisk announced today that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive ...

CAMBRIDGE, MA, USA I June 18, 2025 I Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy ...

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced ...

ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial ...

HANGZHOU, China I September 30, 2024 I Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and ...

PLANEGG-MARTINSRIED, Germany I June 28, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH (“Klinge”) announce that the U.S. Food and Drug Administration (“FDA”) ...

SK Biopharmaceuticals to have exclusive option rights to the compounds for commercialization, while Ubix Therapeutics to receive upfront, milestone payments upon development REPUBLIC of KOREA I April ...

DOVER, DE, USA I June 20, 2025 I Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics”), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class ...

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...

SAN FRANCISCO, CA, USA I December 18, 2018 I Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today ...

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, CA, USA I July 30, 2025 I EuMentis Therapeutics, Inc., (“EuMentis”), a clinical-stage drug development company focused on advancing ...

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...